The Effect of PAI-1 4G/5G Polymorphism and Clinical Factors on Coronary Artery Occlusion in Myocardial Infarction.
OBJECTIVE
Data on the impact of PAI-1-675 4G/5G genotype for fibrinolysis during myocardial infarction are inconsistent. The aim of our study was to evaluate the association of clinical and genetic (PAI-1-675 4G/5G polymorphism) factors with coronary artery occlusion in patients with myocardial infarction.


METHODS
PAI-1-675 4G/5G detection was achieved by using Sanger sequencing in a sample of patients hospitalized for stent implantation due to myocardial infarction. We categorized the patients into two groups: patients with coronary artery occlusion and patients without coronary artery occlusion according to angiographic evaluation.


RESULTS
We identified n = 122 (32.4%) 4G/4G, n = 186 (49.5%) 4G/5G, and n = 68 (18.1%) 5G/5G PAI-1 genotype carriers. Univariate and multivariate analysis showed that only the 4G/5G genotype was associated with coronary artery occlusion (OR: 1.656 and 95% CI: 1.009-2.718, p = 0.046).


CONCLUSIONS
Our results showed that carriers of PAI-1 4G/5G genotype with myocardial infarction have increased odds of coronary artery occlusion more than 1.6 times in comparison to the carriers of homozygous genotypes.
Institute of Cardiology, Lithuanian University of Health Sciences, Sukileliu 17, LT-50009 Kaunas, Lithuania.
Tajinder Kumar
TK
Parpugga
Institute of Cardiology, Lithuanian University of Health Sciences, Sukileliu 17, LT-50009 Kaunas, Lithuania.
Vacis
V
Tatarunas
Institute of Cardiology, Lithuanian University of Health Sciences, Sukileliu 17, LT-50009 Kaunas, Lithuania.
Vilius
V
Skipskis
Institute of Cardiology, Lithuanian University of Health Sciences, Sukileliu 17, LT-50009 Kaunas, Lithuania ; Department of Cardiology, Lithuanian University of Health Sciences, Eiveniu 2, LT-50009 Kaunas, Lithuania.
Nora
N
Kupstyte
Department of Cardiology, Lithuanian University of Health Sciences, Eiveniu 2, LT-50009 Kaunas, Lithuania.
Diana
D
Zaliaduonyte-Peksiene
Institute of Cardiology, Lithuanian University of Health Sciences, Sukileliu 17, LT-50009 Kaunas, Lithuania.
Vaiva
V
Lesauskaite
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D003324:Coronary Artery Disease / Q000150:complications / Q000235:genetics* / Q000473:pathology; D005260:Female; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications / Q000235:genetics* / Q000473:pathology; D017395:Plasminogen Activator Inhibitor 1 / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide
D017395:Plasminogen Activator Inhibitor 1; C051321:SERPINE1 protein, human